Wednesday, August 31, 2016 10:23:46 AM
Medivation (MDVN) Bidding War Was Hotter Than the Market Even Thought
Before reaching a definitive $14 billion agreement with Pfizer (NYSE: PFE), the market knew Medivation (NASDAQ: MDVN) was in hot demand... but just how hot may have been underestimated.
In its proxy filing after the close Tuesday, Medivation disclosed that in addition to Pfizer, four other suitors submitted bids and two others bid over $80 per share at the end of the sale process ($81.50 was the agreed upon price with Pfizer).
(First there were 5) On August 8, 2016, each of the Interested Parties submitted non-binding written preliminary proposals for the acquisition of Medivation. Pfizer submitted a preliminary proposal for the all-cash acquisition of Medivation for $65.00 per Share. Company 1 submitted a preliminary proposal for the all-cash acquisition of Medivation for $71.00 per Share. Company 2 submitted a preliminary proposal for the all-cash acquisition of Medivation for $62.00—$64.00 per Share. Company 3 submitted a preliminary proposal to acquire Medivation for $60.00 per Share in cash, plus CVRs of up to $10.00 per Share, conditioned on certain revenue metrics. Company 4 submitted a preliminary proposal to acquire Medivation for $63.00 per Share in cash, plus CVRs of up to $5.00 per Share conditioned on certain regulatory milestones for pipeline assets.
(Then there was 4) Company 4 later dropped out of the bidding, but Pfizer, Company 1, Company 2, and Company 3 all submitted higher offers:
On Friday, August 19, 2016, each of Pfizer, Company 1, Company 2, and Company 3 submitted a definitive proposal for an all-cash acquisition of Medivation. Company 4 declined to submit a definitive proposal and ceased participation in the strategic transaction process. The definitive proposals, in order of increasing valuation, were from Company 3 for $72.50 per Share in cash, Company 1 for $73.00 per Share in cash, Company 2 for $75.50 per Share in cash, and Pfizer for $77.00 per Share in cash. Together with their definitive proposals, each of Company 1 and Company 3 also submitted a revised version of the merger agreement.
(Then there was 3) Company 3 dropped out the evening of August 19, 2016. However, on August 20, Pfizer, Company 1, and Company 2 submitted a final proposal.
Later that morning, on August 20, 2016, beginning at 11:51 a.m. Pacific Time, each of Pfizer, Company 1, and Company 2 submitted a final proposal, each of which had been approved by the board of directors of the respective bidding party and each of which included confirmation that it was not subject to further diligence, and a revised draft of the merger agreement. Pfizer submitted a revised final proposal to acquire Medivation for $81.50 per share. Company 1 submitted a revised final proposal to acquire Medivation for $80.25 per share. Company 2 submitted a revised final proposal to acquire Medivation for $80.00 per share.
(Then there was 1) Medivation agreed to be acquired by Pfizer for $81.50 per share.
The full proxy can be found here.
http://www.streetinsider.com/Mergers+and+Acquisitions/Medivation+%28MDVN%29+Bidding+War+Was+Hotter+Than+the+Market+Even+Thought/11989597.html
Recent AMRN News
- Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference • GlobeNewswire Inc. • 05/06/2024 12:00:00 PM
- Amarin Reports First Quarter 2024 Business Update and Financial Results • GlobeNewswire Inc. • 05/01/2024 11:00:00 AM
- Amarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event • GlobeNewswire Inc. • 04/24/2024 06:00:01 PM
- Amarin Announces Results of Annual General Meeting of Shareholders • GlobeNewswire Inc. • 04/22/2024 12:00:25 PM
- Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024 • GlobeNewswire Inc. • 04/15/2024 12:00:00 PM
- Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24 • GlobeNewswire Inc. • 04/08/2024 12:00:00 PM
- New REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups • PR Newswire (Canada) • 04/08/2024 10:30:00 AM
- New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups • GlobeNewswire Inc. • 04/06/2024 07:30:00 PM
- Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe • GlobeNewswire Inc. • 04/03/2024 12:00:00 PM
- Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo • GlobeNewswire Inc. • 03/25/2024 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 03/04/2024 10:30:53 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/04/2024 01:00:24 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/29/2024 12:06:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/29/2024 12:05:56 PM
- Amarin Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/29/2024 12:00:00 PM
- Amarin to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference on February 29, 2024 • GlobeNewswire Inc. • 02/15/2024 01:00:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 02/12/2024 01:00:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:31:50 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:30:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:30:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:30:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:30:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:30:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/26/2024 12:00:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/24/2024 09:31:21 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM